Rumsfeld's Co. Gilead Sciences has nearly quadrupled its profits since Rummy entered the Bush Administration. How? By selling false hope to AIDS patients in poor countries, selling bogus smallpox treatments to the US government, and taking millions from Bill Gates to test HIV drugs on poor people in Cambodia, Africa, and India. And that is probably just the tip of the dirty iceberg.
This article also includes info on DynPort and BioPort. DynPort has scooped up huge anti-bioterror contracts from Bush - even though they have been proven incompetent, even though they are part of Dyncorps, which, in Bosnia, was exposed as running a white slave trade ring. Sound too awful to be true. I wish!!
http://baltimore.indymedia.org/newswire/display/5766/index.phpWant to guess how many shares of GILD Rummy holds?
===
GILEAD SCIENCES, INC.: Rumsfeld's Old Company Reaps Benefits of Friends in High Places
From 1997 to 2001, Donald Rumsfeld was chairman of Gilead Sciences Inc., a biopharmaceutical firm in Foster City, Calif. He has also served as a director for Amylin Pharmaceuticals, Inc. and has millions of dollars worth of stock in both Amylin and Gilead, including some 68,200 vested shares in Gilead worth from $1 million to $5 million. Gilead certainly appears to have benefited from having a good friend in a very high place. Since 2001, Gilead sciences revenues have nearly quadrupled (they more than tripled in 2002 alone). How did they do it?
Although we may never find out what and how many strings were pulled, a few strings are dangling out in the open. For one thing, Gilead has scooped up a great big fat chunk of pork through Project Bioshield (see section on smallpox vaccine below). For example,
Bill Gates, who owes the Bush administration big time for getting him out of this anti-trust case with barely a slap on the wrist (relative to what should have been the penalty) has given over $6 million to Gilead Sciences to fund trials of an experimental use of the antiviral HIV drug Viread. These trials are being conducted on poor people in Cambodia, India, and several African nations.
(snip)
In any case, rhere is no doubt that Gilead Sciences has ties to the US government, to the Pentagon in particular. Rumsfeld was replaced at Gilead by Cordell W. Hull, who is now also chairman of the company's Audit Committee. Hull also serves as a director of Bechtel Group, Inc., Bechtel Enterprises and the Fremont Group.
http://dc.indymedia.org/newswire/display/86537/index.phpSchultz also sits at the direction of Gilead Science, the giant of the pharmacy whose Donald Rusmfeld was the chairman until his return to the government. This firm has just obtained important public markets within the framework of the prevention of the chemical and biological attacks. Indeed, Rumsfeld succeeded in convincing its public opinion that the mode of Saddam Hussein would still hold some weapons of massive destruction that it to him had sold itself during the Iran-Iraq war and that Baghdad would plan to use them against the people states-unien. During last years, Gilead Science drew most of its benefit from antiviral which it produces to treat the AIDS. The high price of these treatments not allowing their diffusion in the Third World, several States tried to manufacture some except licence. They were condemned by OMC. In 1998, the antiviral identical ones
were manufactured except licence by a usin E pirate with Al-Shifa (Sudan). At the request of Rumsfeld and Schultz, Bill Clinton showed the Al-Shifa center to be a cover for the manufacture of weapons of massive destruction by Al Qaïda and made it bombard. Various international investigations showed later on that these charges were without bases.
http://usgohome.free.fr/actualite/guerre_english.htm =======
CHIMERIX ANNOUNCES LICENSING DEAL WITH GILEAD SCIENCES
- Chimerix Obtains Rights to Cidofovir for Development of an Oral Drug to Treat Smallpox Infections -
San Diego, CA - September 12, 2003 - Chimerix Inc., an emerging biotechnology company developing orally available, targeted medicines from bioactive molecules, today announced that it has licensed rights from Gilead Sciences, Inc. (Nasdaq: GILD) to develop oral derivatives of Gilead's proprietary antiviral compound cidofovir, intended for the prevention or treatment of smallpox infections. Chimerix's initial focus will be to continue the development of its oral smallpox drug, CMX001, which is a chemically modified derivative of cidofovir, derived by incorporating Chimerix proprietary chemistry to enhance intracellular uptake and oral delivery.
The license permits Chimerix to sell CMX001 to governments anywhere in the world. The license also includes the rights to develop and sell oral derivatives of cidofovir for treatment of infections caused by related viruses such as vaccinia virus (the virus used for smallpox vaccinations) and monkeypox virus (a smallpox-related virus found in animals, which can be passed on to humans). Chimerix will pay Gilead royalties based on a percentage of net sales to governments. Specific terms of the agreement were not disclosed.
Cidofovir is an antiviral medication currently approved for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients. Marketed under the brand name Vistide®, Gilead's drug was cleared for marketing by the U.S. Food and Drug Administration in 1996 and by European regulators in 1997. Cidofovir is administered by intravenous infusion. Using proprietary technology, Chimerix is able to modify cidofovir (the parent compound), to yield a potent, orally available drug that has the potential to treat smallpox infections, or complications of smallpox vaccination. Chimerix was recently awarded a $36.1M grant from U.S. National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), under the Bioterrorism Act of 2002, to support development for its drug, CMX001, as a treatment for smallpox. The Bioterrorism Act of 2002 authorizes government spending for the National Pharmaceutical Stockpile.
(snip)
http://www.chimerix-inc.com/news_091203.htm ====
Riordan ceded his position as company president to Martin in 1996, and eventually left the board of directors, which had a stunning lineup of his recruits, including Donald Rumsfeld, who later left Gilead to become President Bush's secretary of Defense. Through Rumsfeld and his connections in the Republican elite, the Gilead board also landed former Secretary of State George Schultz. Also serving on the board are Nobel Prize winner and Stanford Professor Paul Berg and Intel co-founder and chairman emeritus Gordon Moore.
(snip)
Gilead's products and pipeline
Marketed products: ----- Therapeutic area: ----- 2002 revenues:
Viread --------------------- HIV/AIDS -------------- $226 million
AmBisome --------------- Fungal infection ------ $202 million
Hepsera ---------------- Chronic hepatitis B ---- $6 million
Tamiflu ------------------- Influenza A & B -------- $4 million
Vistide ---------------- CMV retinitis/AIDS ------ $4 million
DaunoXome -------------- Kaposi's sarcoma -------- $3 million
Experimental drugs: ---- Therapeutic area: ---- Clinical trials phase:
Emtricitabine ------------- HIV/AIDS ------------- Submitted for approval
Chronic hepatitis B ------- Phase III
Amdoxovir -------------- HIV/AIDS ------------- Phase I/II
Tenofovir topical gel -- HIV/AIDS ------------- Phase I/II
Clevudine -------------- Chronic hepatitis B -- Phase I/II
GS 7340 ---------------- HIV/AIDS ------------- Phase I/II
http://www.aegis.com/news/sc/2003/SC030405.html